Onboarding and Supporting New Providers Are Your Responsibilities as an APRN Leader
Contributing to the orientation and onboarding of new advanced practice RN (APRN) providers supports optimal patient outcomes, professional satisfaction, and nurse retention. Orientation involves working through the hospital’s training program, policies and procedures, organizational structures, and mission or vision statements, whereas onboarding builds engagement and relationships in the organization over many weeks to months. Some institutions have formalized, detailed processes for orientation and onboarding, but others may offer very little structure and support.
- Read more about Onboarding and Supporting New Providers Are Your Responsibilities as an APRN Leader
- Add new comment
FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer
On April 13, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sacituzumab govitecan (Trodelvy®) for patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor.
- Read more about FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer
- Add new comment
Latina, Asian Women With Gynecologic Cancers Are Less Likely to Use Palliative Care
Only 4%–9% of patients with ovarian or cervical cancer use palliative care, but the numbers are much lower for Hispanic and Asian women than for non-Hispanic White women, according to researchers’ findings reported in Data in Brief.
- Read more about Latina, Asian Women With Gynecologic Cancers Are Less Likely to Use Palliative Care
- Add new comment
Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer
Once patients stop responding to platinum-based chemotherapy for locally advanced or metastatic urothelial cancer, their treatment options had been somewhat limited: PD-1/PD-L1 inhibitors were effective in only 13%–29% of patients and taxanes in only 11%–13%. When the antibody drug conjugate enfortumab vedotin was approved in late 2019, it offered new hope for patients and providers, with clinical trials reporting a 44% objective response rate.
- Read more about Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer
- Add new comment
Involve the Entire Cancer Care Team to Effectively Implement Guidelines
Only 19% of strategies to implement clinical practice guidelines are fully effective and the majority (43%) are not effective at all, according to the findings from a clinical review in the European Union. Effective guideline implementation requires teamwork, interprofessional engagement, and selecting the most appropriate tool for the job.
- Read more about Involve the Entire Cancer Care Team to Effectively Implement Guidelines
- Add new comment
The Case of the Targeted Therapy Toxicity
Tyrone is a 74-year-old man with a history of acute myeloid leukemia (AML), type 2 diabetes, and hypertension who was admitted to the hospital after lab results revealed 40% circulating blasts in his peripheral blood that was concerning for relapsed disease. He was diagnosed with AML three years ago and achieved remission after treatment with a hypomethylating agent.
Biden-Harris Administration Invests $10 Billion to Address Disparities in Vaccine Confidence and Distribution
The Biden-Harris administration to strengthen public perception of COVID-19 coronavirus vaccines and ensure all Americans, including communities of color, those in rural areas, low-income populations, and other underserved communities in the pandemic response, receive their vaccinations.
- Read more about Biden-Harris Administration Invests $10 Billion to Address Disparities in Vaccine Confidence and Distribution
- Add new comment
Nursing Considerations for Head and Neck Cancer Survivorship Care
Despite accounting for only 3% of all cancer survivors, patients with head and neck cancers often require significant support and survivorship care. And oncology nurses can expect survivorship to grow with recent improvements in prognosis and treatment options, such as with reductions in human papillomavirus-related oropharyngeal cancers, which tend to affect young people and offer improved long-term survival rates.
FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer
On April 7, 2021, the U.S. Food and Drug Administration (FDA) granted regular approval to sacituzumab govitecan (Trodelvy®) for patients with unresectable locally advanced or metastatic triple-negative breast cancer who received two or more prior systemic therapies, at least one of which for metastatic disease.
Biden Establishes Gender Council to Advance Equity and Equality for Women
Although society has tried to take steps to confront gender disparities, women remain underrepresented across various sectors. Title IX in 1972 granted every American student the right to education without gender discrimination. However, female students still bear the brunt of sex-segregated programs and gender-based violence, two major obstacles to educational equality. Women consistently earn less than their male counterparts. The wage gap is larger for most women of color, and gender discrimination and sexual harassment in the workplace perpetuate economic divides. More women work today than ever before, but they face barriers to leadership roles, such as stereotypes about their performance abilities, uneven demands of motherhood compared to male partners, and the reality that many workplaces prefer and reward masculine leadership styles. Health needs are substantially greater for older women compared to older men, but women reported fewer visits with a physician and lesser likelihood to stay in a hospital.